Sequence assignments in partially replicate design [Design Issues]

posted by Loky do – Egypt, 2020-07-19 01:33 (273 d 23:44 ago) – Posting: # 21746
Views: 1,162


In partially replicate 3-way design, FDA recommends using the following example for sequence assignments 1,2,3 --> (TRR, RTR, RRT), if we used different sequence assignments 1,2,3 --> (TRR, RRT, RTR), is this change significant? or is it ok as long as it's considered in statistical analysis?

Thanks in advance

Complete thread:

 Admin contact
21,419 posts in 4,475 threads, 1,509 registered users;
online 18 (0 registered, 18 guests [including 2 identified bots]).
Forum time: Monday 01:17 CEST (Europe/Vienna)

There is one certainty in drug development
and statistics that one can depend on:
the data are always late.    Scott Patterson and Byron Jones

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz